A Phase 2 interventional study of Allogeneic hemopoietic stem cell transplant in Ewing and Soft Tissue Sarcoma, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Status unknown at 1 site in Italy. Open to participants aged 1 Month to 60 Years. Per ClinicalTrials.gov, last updated 2009-10-20.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Phase 2, Interventional, and Treatment
This is a perspective multicentric study for the treatment of patients aged equal or less than 60 years and submitted to an allogeneic hematopoietic stem cell transplantation from an HLA compatible related or unrelated donor because affected by resistent or refractory or relapsed after autologous stem cell transplantation Ewing Sarcoma or Soft tissues sarcoma who did not benefit from conventional therapy.
1,667 studies on the registry are indexed under Sarcoma; 393 are open to participants now.
This study's enrollment of 140 is above the median of 40 across 1,283 interventional studies indexed under Sarcoma.
Browse Sarcoma studies →IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 493 studies on the registry; 273 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
All the patient who are affected by refractory or resistant or relapsed Soft tissue sarcoma o Ewing sarcoma who find an HLA compatible allogeneic donor and are submitted to Stem cell transplantation
Procedure: Allogeneic hemopoietic stem cell transplant
administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell
Also known as: CE_clin.42_2009_S_sper
Progression Free Survival (PFS) a 12 months from the enrollment higher than 30% for the patients submitted to allogeneic stem cell transplantation in front of the patients who received conventional chemotherapy.
Time frame: 12 months from the enrollement
Transplant related mortality
Time frame: 12 months after the enrollement of the first patients
This study is status unknown, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna